Association between pediatric psoriasis and the metabolic syndrome

Au, Shiu Chung; Goldminz, Ari M.; Loo, Daniel S.; Dumont, Nicole; Levine, Danielle; Volf, Eva; Michelon, Melissa; Wang, Andrew; Kim, Noori; Yaniv, Shimrat; Lizzul, Paul F.; Kerensky, Todd; Lopez-Benitez, Jorge M.; Natter, Marc D.; Miller, Laurie C.; Pelajo, Christina F.; Davis, Tal; Gottlieb, Alice B.

doi:10.1016/j.jaad.2011.11.935

Cited by 53 publications

(38 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence was 14.5% in those aged ≥10 years compared with 30% from other studies 28 29. The prevalence of obesity in CCOP in our study (8.7%) was higher than reported from ‘normal’ Indian children (3.4%) 30.…”

Section: Discussioncontrasting

confidence: 74%

Clinical profile of childhood-onset psoriasis and prevalence of HLA-Cw6: a hospital-based study from India

Sathishkumar

George

Daniel

et al. 2015

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 74%

Clinical profile of childhood-onset psoriasis and prevalence of HLA-Cw6: a hospital-based study from India

Sathishkumar

George

Daniel

et al. 2015

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

“…The risk profile for our younger patients is still under investigation, but a pattern linking psoriasis and the metabolic syndrome seems to be emerging [1,8,9,13,20,[28][29][30][31][32][33][34].…”

Section: Comorbiditiesmentioning

confidence: 99%

“…Multiple authors, including Au et al [31], Koebnick et al [32], and Volf et al [33], state that pediatric psoriasis patients should be monitored for cardiovascular risk factors and, if found at risk, should receive preventive interventions [34]. tywnie wpływa na jakość życia pozostałych członków rodziny [1,5,[24][25][26].…”

Section: Comorbiditiesmentioning

confidence: 99%

Childhood psoriasis

Piekarska-Myślińska¹,

Pietrzak²,

Myśliński³

et al. 2017

View full text Add to dashboard Cite

Psoriasis is a long-lasting inflammatory skin disease with an autoimmunological and immunometabolic background. The latest European data indicate that the occurrence of psoriasis in children ranges from 0.7% to 2.1%. Despite distinct clinical characteristics, this disease continues to cause diagnostic difficulties and is often incorrectly diagnosed. The goal of this article is to present the course of psoriasis in children, basic diagnostic techniques, including dermoscopy, influence of the disease on the quality of life and risk of co-morbidity development. The therapeutic approcach to childhood psoriasis is presented. StreSzCzenieŁuszczyca jest przewlekłą chorobą zapalną skóry o podłożu autoimmunologicznym i immunometabolicznym. Według najnowszych danych europejskich zapadalność na łuszczycę u dzieci wynosi 0,7-2,1%. Pomimo charakterystycznego obrazu klinicznego schorzenie to nadal sprawia trudności diagnostyczne i bywa mylone z innymi chorobami. Celem niniejszej pracy jest omówienie odmienności przebiegu łuszczy-cy u dzieci, podstaw diagnostyki z uwzględnieniem obrazu dermatoskopowego, wpływu na jakość życia i sferę emocjonalną, zagrożenia rozwojem innych chorób, zwłaszcza dziecięcego zespołu metabolicznego oraz odmienności stosowanych metod terapeutycznych.

show abstract

“…Multivariate analysis models adjusted for age, gender and smoking condition of psoriasis patients showed that psoriasis was consistently associated with MS. 11 There are also indications that the severity of psoriasis has direct relation to the increased risk for the development of MS. 12 The increased prevalence of MS and its components seem to also be present in children with psoriasis. 13,14 …”

Section: Metabolic Syndrome and Psoriasismentioning

confidence: 99%

Psoriasis comorbidities: complications and benefits of immunobiological treatment

Carvalho¹,

Romiti²,

Souza³

et al. 2016

An. Bras. Dermatol.

View full text Add to dashboard Cite

During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients.

show abstract

Association between pediatric psoriasis and the metabolic syndrome

Cited by 53 publications

References 5 publications

Clinical profile of childhood-onset psoriasis and prevalence of HLA-Cw6: a hospital-based study from India

Clinical profile of childhood-onset psoriasis and prevalence of HLA-Cw6: a hospital-based study from India

Childhood psoriasis

Psoriasis comorbidities: complications and benefits of immunobiological treatment

Contact Info

Product

Resources

About